At a glance
ClinicalIndex Comparison Record- ✓Meets DSM-IV criteria for nicotine dependence with Fagerstrom Test of Nicotine Dependence (FTND) score greater than 5
- ✓Smokes at least 15 cigarettes daily (averaged over 1 week within the month prior to enrollment)
- ✓Motivated to quit smoking within 30 days at time of initial evaluation
- ✓At least one unsuccessful attempt to quit smoking in the past year
- ✕Currently taking sympathomimetic agents (e.g., pseudoephedrine, methylphenidate)
- ✕Currently taking antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion) or other monoamine oxidase inhibitors
- ✕Currently taking meperidine (Demerol)
- ✕Serious medical disorders such as unstable angina or liver failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Usefulness of Selegiline for Smoking Cessation
In Brief
A Phase 2 clinical trial evaluating Selegiline and Placebo for Tobacco Use Cessation. Completed, enrolled 101 participants across 1 site.
Detailed Summary
Despite the widespread use of nicotine replacement therapies for the treatment of nicotine dependence, many smokers are still unable to quit smoking. The purpose of this study is to determine the safety and effectiveness of selegiline as an aid to help smokers quit smoking.
Study Details
Timeline
Interventions
5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.